Development Pipeline Overview

Our proprietary technology platform can be used to make a Navacim directed toward any autoimmune disorder where disease pathogenesis is associated with an identifiable autoreactive, or self-antigen — in other words all conventionally classified autoimmune disorders and many others, including cancer. In most diseases there are multiple self-antigens to choose from, though not every antigen is present in every patient and some are far more common than others. An appropriately designed Navacim for a given disease contains an antigenic determinant that encompasses the widest possible patient population.

The accompanying table shows our progress to date and the clinical indications of immediate interest. Our most advanced program is in Type 1 Diabetes (T1D), followed very closely by Multiple Sclerosis, but it is important to note that Navacims are highly modular and any two share greater than 95% identity. This means that processes and assays developed for one Navacim can be readily adapted to another. This is particularly true when it comes to large scale Navacim manufacturing and assembly for late preclinical and clinical testing, and beyond. We anticipate that these advantages will significantly reduce the development time for each subsequent Navacim emerging from the platform.